The selective cyclooxygenase-2 inhibitor celecoxib is a sale alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs;Der selektive cyclooxygenase-2-inhibitor celecoxib ist ein sicheres ausweichpräparat bei intoleranz gegenüber nichtsteroidalen antiphlogistika

Medizinische Klinik

Volumn 98, Issue 5, 2003, Pages 242-244

  Ahlbach, Sandra ^a   Usadel, Klaus Henning ^a   Kaufmann, Roland ^b   Boehncke, Wolf Henning ^b  

^a Zentrum der Inneren Medizin   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Adverse reaction; Celebrex ; Coxibs; Cyclooxygenase; NSAID; Urticaria

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATCH TEST; PRICK TEST; SINGLE BLIND PROCEDURE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INTRADERMAL TESTS; MALE; MIDDLE AGED; PYRAZOLES; SINGLE-BLIND METHOD; SULFONAMIDES;

EID: 0038288003     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-003-1251-3     Document Type: Article

References (23)

1. ACR Clinical Guidelines Committee. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
2. Arzneimittelkommission der deutschen Ärzteschaft. Akute interstitielle Nephritis durch Celecoxib (in Deutschland Celebrex(r)). Dtsch Ärztebl 2003; 100:C189.
3. Asero R. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol 1999;82:554-8.
4. Bianco S, Robuschi M, Petrigni G, Scuri M, Pieroni MG, Refini RM, Vaghi A, Sestini PS. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46:115-20.
5. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998;25:Suppl 51:2-7.
6. Brune K, Kalden J, Zacher J, Zeilhofer HU. Delektive Inhibitoren der Zyklooxygenase 2: Evolution oder Revolution. Dtsch Arztebl 2000;97:1818-25.
7. Clement D, Goa K Celecoxib. Drugs 2000; 59:957-80.
8. Fu JY, Masferrer JL, Seibert K, Raz A, Needlemean P. The induction and suppression of prostaglandin H2 synthase (cyclooxyenase) in human monocytes. J Biol Chem 1990;265:16737-40.
9. Gierse JK, McDonald JJ, Hauser SD, Rangwela SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996;271:15810-4.
10. Ispano M, Fontana A, Scibilia J, Ortolani C. Oral challenge with alternative nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these drugs. Drugs 1993;46:Suppl 1:253-6.
11. Joint Task Force on Practise Parameters. Practise parameters for the diagnosis and treatment of asthma. J Allergy Clin Immunol 1995;96:707-870.
12. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke W-H. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the resluts of oral provocation. Contact Dermatitis 2002;47:100-2.
13. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53:1231-3.
14. Luong C, Miller A, Barnett J, Chow J, Ramesha C, Browner MF. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996;3:927-33.
15. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, Cocci A, Moretti U, Velo G, Leone R. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999;48:839-46.
16. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24:Suppl 49:6-8.
17. Pacor ML, di Lorenzo G, Biasi D, Barbagallo M, Corrocher R. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32:397-400.
18. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 2001;345:1856.
19. Settimane GA. Aspirin sensitivity and allergy. Biomed Pharmacother 1988;42:493-8.
20. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219-25.
21. Yoshida S, Ishizaki Y, Onuma K, Shoji T, Nakagawa H, Amayasu H. Selective cyclooxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000;106:1201-3.
22. Zeitz HJ. Bronchial asthma, nasal polyps and aspirin sensitivity: Samter's syndrome. Clin Chest Med 1988;9:567-76.
23. Zollner TM, Ahlbach S, Kaufmann R, Boehncke W-H. Verträglichkeit des selektiven Cyclooxygenase-2-Inhibitors Rofecoxib bei Intoleranz gegenüber nicht-steroidalen Antiphlogistika. Dtsch Med Wochenschr 2001;126:386-8.